Addressing Alzheimer's disease tangles: from NAP to AL-108.

@article{Gozes2009AddressingAD,
  title={Addressing Alzheimer's disease tangles: from NAP to AL-108.},
  author={Illana Gozes and Alistair J Stewart and Bruce H. Morimoto and Anthony W Fox and Karole Sutherland and Donald Schmeche},
  journal={Current Alzheimer research},
  year={2009},
  volume={6 5},
  pages={455-60}
}
AL-108 is the intranasal formulation of NAP (a peptide of eight amino acids, NAPVSIPQ). Phase IIa clinical results have recently shown that AL-108 has a positive impact on memory function in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer's disease (AD). The clinical development of AL-108 has been based on extensive studies showing pre-clinical efficacy for NAP. NAP has demonstrated potent neuroprotective activity in vitro and in vivo. Its mechanism of action… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Similar Papers

Loading similar papers…